When is the next results date for Saakshi Medtech?

No Upcoming Board Meetings

Has Saakshi Medtech declared dividend?

No Dividend History Available

What is the technical trend for Saakshi Medtech?

As of June 3, 2025, Saakshi Medtech's trend has shifted to sideways with mixed signals; while the weekly MACD and KST are mildly bullish, daily moving averages and monthly Bollinger Bands indicate a mildly bearish outlook, reflecting overall market indecision.

As of 3 June 2025, the technical trend for Saakshi Medtech has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the daily moving averages indicate a mildly bearish trend. The Bollinger Bands show a bullish signal on the weekly chart but are mildly bearish on the monthly chart. The KST and OBV are both mildly bullish on the weekly timeframe, supporting the sideways trend. Overall, the strength of the trend is weak, reflecting indecision in the market.

Who are the peers of the Saakshi Medtech?

Saakshi Medtech's peers include Modison, Supreme Power, Shivalic Power, and others, with varying management risks and growth rates. Saakshi Medtech has good management risk and below-average growth, with a 1-year return of -31.85%.

Peers: The peers of Saakshi Medtech are Modison, Supreme Power, Shivalic Power, Prizor Viztech, Kaycee Inds., Hind.Urban Infra, GEE, Eppeltone Ene., and Lak. Electrical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shivalic Power, Prizor Viztech, and the rest. Good management risk is found at Saakshi Medtech, while Average management risk is present at Modison, Supreme Power, Kaycee Inds., and the rest. Below Average management risk is noted at Hind.Urban Infra, GEE, Lak. Electrical, and the rest. Growth is Excellent at Supreme Power, Shivalic Power, Prizor Viztech, while Below Average growth is seen at Saakshi Medtech, Modison, and the rest. Average growth is noted at Kaycee Inds., and the rest. Below Average growth is also observed at Hind.Urban Infra, GEE, and Lak. Electrical. Capital Structure is Excellent at Modison and Lak. Electrical, Good at Saakshi Medtech and Kaycee Inds., Average at Supreme Power, Shivalic Power, Prizor Viztech, and the rest, and Below Average at Hind.Urban Infra, GEE, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Modison with N/A, while the peer with the lowest is Supreme Power at -39.20%, and Saakshi Medtech's 1-year return is -31.85%, which is better than Supreme Power's. Additionally, Shivalic Power, Hind.Urban Infra, and Lak. Electrical have negative six-month returns.

What does Saakshi Medtech do?

Saakshi Medtech & Panels Ltd is a Micro Cap company in the Other Electrical Equipment industry, originally incorporated in 2009. It has a market cap of INR 353 Cr, with a P/E ratio of 75.00 and a return on equity of 5.05%.

Overview:<BR>Saakshi Medtech & Panels Ltd operates in the Other Electrical Equipment industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as a Private Limited Company under the name "Saakshi Machine and Tools Private Limited" on March 25, 2009. It later took over the business of the proprietorship concern of Lt. Vijay Laxman Latkar, M/s Supreme Industry on January 27, 2012. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 353 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 75.00<BR>Industry P/E: 66<BR>Dividend Yield: 0.00%<BR>Debt Equity: 0.03<BR>Return on Equity: 5.05%<BR>Price to Book: 3.77<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the top shareholders of the Saakshi Medtech?

The top shareholders of Saakshi Medtech include promoter Chitra Vijay Latkar with 66.27%, individual investors with 22.37%, and public shareholder Jatinder Agarwal at 4.84%. There are no pledged promoter holdings or mutual funds invested in the company.

The top shareholders of Saakshi Medtech include the promoters, with Chitra Vijay Latkar holding the largest share at 66.27%. Additionally, individual investors collectively own 22.37% of the company. The highest public shareholder is Jatinder Agarwal, who holds 4.84%. There are also two foreign institutional investors (FIIs) that hold a combined 0.1%. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

How big is Saakshi Medtech?

As of 24th July, Saakshi Medtech & Panels Ltd has a market capitalization of 338.00 Cr, classifying it as a Micro Cap, with shareholder's funds of 93.33 Cr and total assets of 130.54 Cr; however, recent financial data for the last four quarters is unavailable.

As of 24th July, <BR><BR>Market Cap: Saakshi Medtech & Panels Ltd has a market capitalization of 338.00 Cr, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 93.33 Cr and Total Assets totaling 130.54 Cr.

Is Saakshi Medtech overvalued or undervalued?

As of November 6, 2025, Saakshi Medtech is considered very expensive and overvalued with a PE ratio of 65.09, an EV to EBITDA ratio of 31.15, and a year-to-date return of -22.64%, significantly underperforming compared to its peers and the Sensex.

As of 6 November 2025, the valuation grade for Saakshi Medtech has moved from expensive to very expensive. The company is currently overvalued, indicated by a PE ratio of 65.09, an EV to EBITDA ratio of 31.15, and a Price to Book Value of 3.13. In comparison to its peers, Adani Enterprises has a PE ratio of 127.79 and an EV to EBITDA of 29.94, while Tata Chemicals shows a PE of 60.22 and an EV to EBITDA of 16.15, suggesting that Saakshi Medtech's valuation is significantly higher than many of its competitors.<BR><BR>The company's recent performance has also been underwhelming, with a year-to-date return of -22.64%, contrasting sharply with the Sensex's gain of 7.89% over the same period. This further reinforces the notion that Saakshi Medtech is not only overvalued but also struggling to deliver returns in the current market environment.

How has been the historical performance of Saakshi Medtech?

Saakshi Medtech has experienced a decline in key financial metrics, with net sales and operating profit decreasing from Mar'23 to Mar'25, while total assets and liabilities increased. Cash flow from operations also fell significantly, indicating reduced profitability despite asset growth.

Answer:<BR>The historical performance of Saakshi Medtech shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Saakshi Medtech's net sales have decreased from 122.06 Cr in Mar'23 to 92.43 Cr in Mar'25, reflecting a downward trend. The total operating income followed a similar pattern, dropping from 122.06 Cr in Mar'23 to 92.43 Cr in Mar'25. The raw material costs also decreased from 73.93 Cr in Mar'23 to 58.81 Cr in Mar'25, indicating a reduction in production costs. Operating profit (PBDIT) saw a decline from 20.70 Cr in Mar'23 to 10.88 Cr in Mar'25, with the operating profit margin decreasing from 16.84% to 11.15%. Profit before tax fell from 16.59 Cr in Mar'23 to 6.59 Cr in Mar'25, leading to a profit after tax of 4.71 Cr in Mar'25, down from 12.38 Cr in Mar'23. The company's total assets increased from 93.24 Cr in Mar'23 to 131.10 Cr in Mar'25, while total liabilities also rose from 93.24 Cr to 131.10 Cr in the same period. Cash flow from operating activities decreased from 10.00 Cr in Mar'23 to 3.00 Cr in Mar'25, contributing to a net cash outflow of 12.00 Cr in Mar'25. Overall, Saakshi Medtech's financial performance has shown a decline in profitability and cash flow, despite an increase in total assets and liabilities.

Which are the latest news on Saakshi Medtech?

Why is Saakshi Medtech falling/rising?

As of 04-Dec, Saakshi Medtech & Panels Ltd's stock price is rising to 192.90, reflecting a 1.98% increase. This short-term gain contrasts with a year-to-date decline of 12.32%, indicating mixed signals about its longer-term performance.

As of 04-Dec, Saakshi Medtech & Panels Ltd's stock price is rising, currently at 192.90, with a change of 3.75 (1.98%) upward. This increase can be attributed to the stock's performance over the past week, where it has risen by 5.96%, significantly outperforming the benchmark Sensex, which has declined by 0.69% during the same period. Additionally, the stock has shown a positive trend over the past month, with an increase of 11.09%, while the Sensex has only gained 1.70%. <BR><BR>Despite these short-term gains, it is important to note that the stock has underperformed in the year-to-date comparison, with a decline of 12.32% compared to the Sensex's increase of 10.10%. Furthermore, today's performance indicates that the stock has underperformed its sector by 1.78%. The moving averages suggest that while the stock is currently above its 5-day, 20-day, and 200-day moving averages, it remains below the 50-day and 100-day moving averages, indicating mixed signals regarding its longer-term trend.<BR><BR>Investor participation appears to be declining, as evidenced by a drop in delivery volume by 10.84% against the 5-day average. However, the stock remains liquid enough for trading, which may support its current price rise. Overall, the recent upward movement in the stock price is primarily driven by its strong short-term performance relative to the market and sector, despite some underlying concerns regarding longer-term trends and investor engagement.